Table 5.
Effects of CMJE on serum ALT, AST, uric acid and creatinine levels.
| Treatment groups | ALT (U/L) | AST (U/L) | Uric acid (mg/dL) | Creatinine (mg/dL) |
|---|---|---|---|---|
| NC | 71.60 ± 2.40a | 4.80 ± 1.76a | 6.60 ± 2.40a | 0.49 |
| DC | 33.75 ± 2.50b | 7.62 ± 2.00b | 12.00 ± 2.80b | 1.23 |
| CMJE50 | 73.5 0 ± 7.20a | 6.00 ± 1.2 0c | 6.30 ± 0.72a | 0.71 |
| CMJE100 | 80.00 ± 8.00a | 5.17 ± 1.04c | 6.59 ± 0.82a | 0.77 |
| CMJE200 | 79.00 ± 8.10a | 6.50 ± 0.85b | 7.18 ± 0.71c | 0.68 |
Data are expressed as means ± SD (n = 6). All data were analyzed by one-way ANOVA (analysis of variance) using the statistical software SPSS (IBM Corporation, NY, version 20.0) followed by Tukey's post hoc test for significance at P ≤ 0.05. The significant differences among and between the groups at least in the experimental condition are represented through the superscript letters (a–c) in the table.